189 related articles for article (PubMed ID: 32527769)
1. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Buderath P; Mairinger F; Mairinger E; Böhm K; Mach P; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A; Westerwick D; Hager T
Int J Gynecol Cancer; 2019 Nov; 29(9):1389-1395. PubMed ID: 31492714
[TBL] [Abstract][Full Text] [Related]
3. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Zong L; Zhou Y; Zhang M; Chen J; Xiang Y
Cancer Immunol Immunother; 2020 Jan; 69(1):33-42. PubMed ID: 31781843
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C
J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449
[TBL] [Abstract][Full Text] [Related]
8. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ
J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813
[TBL] [Abstract][Full Text] [Related]
9. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
10. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
11. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
Parvathareddy SK; Siraj AK; Al-Badawi IA; Tulbah A; Al-Dayel F; Al-Kuraya KS
Sci Rep; 2021 Feb; 11(1):3750. PubMed ID: 33580098
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
[TBL] [Abstract][Full Text] [Related]
15. Infiltrating T lymphocytes and programmed cell death protein-1/programmed death-ligand 1 expression in endometriosis-associated ovarian cancer.
Nero C; Romito I; Spadola S; Romito A; Turco LC; Cosentino F; De Ninno M; Catena U; De Cicco Nardone A; Moroni R; Zannoni G; Fagotti A; Scambia G
Fertil Steril; 2022 Jan; 117(1):160-168. PubMed ID: 34656305
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
17. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
19. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
20. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
